Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 3/20 | 0.49 |
| ▸ | CA2 | P00918 | 3/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SIRT5 | Q9NXA8 | 3/20 | 0.46 |
| ▸ | SIRT2 | Q8IXJ6 | 6/20 | 0.45 |
| ▸ | SIRT1 | Q96EB6 | 5/20 | 0.45 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.45 |
| ▸ | TGM2 | P21980 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19017845 | 1.00 | MAPT (0.49) | MAPTTDP1KDM4EGLAGAA | |
| SCHEMBL12285414 | 0.92 | PSMB8 (0.47) | MAPTTDP1PAX8CA1CA2 | |
| SCHEMBL17650866 | 0.91 | CA1 (0.50) | MAPTTDP1KDM4EGLAGAA | |
| SCHEMBL18332009 | 0.88 | CA1 (0.45) | MAPTTDP1KDM4EGLAGAA | |
| SCHEMBL16847607 | 0.88 | MAPT (0.49) | MAPTTDP1KDM4EGLAGAA | |
| SCHEMBL18100002 | 0.87 | SIRT2 (0.44) | SIRT5SIRT2SIRT1SIRT3TGM2 | |
| SCHEMBL20067639 | 0.86 | CA1 (0.64) | MAPTTDP1KDM4EGLAGAA | |
| SCHEMBL24997166 | 0.85 | MAPT (0.43) | MAPTTDP1KDM4EGLAGAA | |
| SCHEMBL17661281 | 0.85 | SIRT2 (0.50) | SIRT2SIRT1SIRT3TGM2 | |
| SCHEMBL17039831 | 0.84 | SIRT5 (0.61) | MAPTSIRT5SIRT2SIRT1SIRT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3082875-B1 | PEPTIDOMIMETIC COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF | GENENTECH INC (US) | 2020-11-25 | — | — | EP | disclosed |
| US-10632210-B2 | Peptidomimetic compounds and antibody-drug conjugates thereof | GENENTECH, INC. (US) | 2020-04-28 | — | — | US | disclosed |
| US-20190083643-A1 | PEPTIDOMIMETIC COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF | GENENTECH, INC. (US) | 2019-03-21 | — | — | US | disclosed |
| US-10017577-B2 | Antibodies and immunoconjugates | GENENTECH, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-20170174782-A1 | ANTI-HER2 ANTIBODIES AND IMMUNOCONJUGATES | GENENTECH, INC. (US) | 2017-06-22 | — | — | US | disclosed |
| US-20170002086-A1 | ANTIBODIES AND IMMUNOCONJUGATES | GENENTECH, INC. (US) | 2017-01-05 | — | — | US | disclosed |
| US-20170002086-A1 | ANTIBODIES AND IMMUNOCONJUGATES | GENENTECH, INC. (US) | 2017-01-05 | — | — | US | disclosed |
| WO-2016205176-A1 | ANTIBODIES AND IMMUNOCONJUGATES | GENENTECH, INC. (US) | 2016-12-22 | — | — | WO | disclosed |
| US-20160279261-A1 | PEPTIDOMIMETIC COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF | GENENTECH, INC. (US) | 2016-09-29 | — | — | US | disclosed |
| US-20160279261-A1 | PEPTIDOMIMETIC COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF | GENENTECH, INC. (US) | 2016-09-29 | — | — | US | disclosed |
| WO-2015095227-A2 | PEPTIDOMIMETIC COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF | GENENTECH, INC. (US) | 2015-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170002086-A1 | ANTIBODIES AND IMMUNOCONJUGATES | FCGR3B, CD47, FCGR1A | MAPT 1194/4885TDP1 4264/4885KDM4E 3541/4885 |
| US-10632210-B2 | Peptidomimetic compounds and antibody-drug conjugates thereof | DNPEP, LNPEP, BCR | MAPT 732/4885TDP1 2825/4885KDM4E 3831/4885 |
| US-10017577-B2 | Antibodies and immunoconjugates | FCGR3B, CD47, FCGR1A | MAPT 1194/4885TDP1 4264/4885KDM4E 3541/4885 |
| US-20190083643-A1 | PEPTIDOMIMETIC COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF | DNPEP, LNPEP, BCR | MAPT 732/4885TDP1 2825/4885KDM4E 3831/4885 |
| US-20170174782-A1 | ANTI-HER2 ANTIBODIES AND IMMUNOCONJUGATES | ERBB2, EGFR, ERBB3 | MAPT 1689/4885TDP1 4439/4885KDM4E 3379/4885 |
| US-20160279261-A1 | PEPTIDOMIMETIC COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF | DNPEP, LNPEP, BCR | MAPT 732/4885TDP1 2825/4885KDM4E 3831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.